Introduction: While multiple vaccines are undergoing clinical trial across the globe, we yearn for an FDA approved drug to protect us from the devastating pandemic for the time being. This study aims to determine the effectiveness of Ivermectin when administered as pre-exposure prophylaxis for COVID-19.
Method: An observational study, with 118 healthcare providers who were enrolled purposively, was conducted in a tertiary hospital in Dhaka from May 2020 to August 2020. The subjects were divided into experimental and control groups; and the experimental group received an oral monthly dose of Ivermectin 12mg for 4 months. Both groups were exposed to COVID-19 positive patients admitted in the hospital during the course of study. The symptomatic subjects were evaluated by physical examination, COVID-19 RT-PCR and/or HRCT of chest. Differences between the variables were determined using the Chi-square test and the level of statistical significance was reached when p<0.05.
Result: 73.3% (44 out of 60) subjects in control group were positive for COVID-19, whereas only 6.9% (4 out of 58) of the experimental group were diagnosed with COVID-19 (p-value < 0.05).
Conclusion: Ivermectin, an FDA-approved, safe, cheap and widely available drug, should be subjected to large-scale trials all over the world to ascertain its effectiveness as pre-exposure prophylaxis for COVID-19.
World Health Organization. Coronavirus disease (COVID-19) update. 2020; https://www.who.int/bangladesh/emergencies/coronavirus-disease-(covid-19)-update.
World Health Organization. WHO's COVID-19 response. 2020; https://www.who.int/emergencies/diseases/novel-coronavirus-2019/interactive-timeline.
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020; 178:104787.
Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. Case Series of 100 COVID-19 Positive Patients Treatedwith Combination of Ivermectin and Doxycycline. Journal of Bangladesh College of Physicians and Surgeons. 2020;38(Supplement Issue).
Professor Satoshi Ōmura. 2007; http://www.satoshi-omura.info/biography/.
Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2011;87(2):13-28.
MERCK. Over 30 Years: The Mectizan Donation Program. 2019; https://www.merck.com/stories/mectizan/.
Hopkins A. Treating neglected tropical diseases. Community eye health. 2013;26(82):26-27.
Tielsch JM, Beeche A. Impact of ivermectin on illness and disability associated with onchocerciasis. Tropical Medicine & International Health. 2004;9(4): A45-A56.
MSD. MECTIZAN Donation Program. n.d; https://www.msdresponsibility.com/access-to-health/key-initiatives/mectizan-donation-program/.
Barrows Nicholas J, Campos Rafael K, Powell ST, et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host & Microbe. 2016;20(2):259-270.
Götz V, Magar L, Dornfeld D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Scientific Reports. 2016;6(1):23138.
Lundberg L, Pinkham C, Baer A, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Research. 2013;100(3):662-672.
Nguyen C, Burton T, Kuklinski W, Gray M, Foy BD. Ivermectin for the Control of West Nile Virus Transmission. New Horizons in Translational Medicine. 2015;2(4):127.
Lee YJ, Lee C. Ivermectin inhibits porcine reproductive and respiratory syndrome virus in cultured porcine alveolar macrophages. Archives of Virology. 2016;161(2):257-268.
Azeem S, Ashraf M, Rasheed MA, Anjum AA, Hameed R. Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Pak J Pharm Sci. 2015;28(2):597-602.
Varghese FS, Kaukinen P, Gläsker S, et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antiviral Research. 2016; 126: 117-124.
Wagstaff Kylie M, Sivakumaran H, Heaton Steven M, Harrich D, Jans David A. Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus. Biochemical Journal. 2012;443(3):851-856.
Mastrangelo E, Pezzullo M, De Burghgraeve T, et al. Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug. Journal of Antimicrobial Chemotherapy. 2012;67(8):1884-1894.
Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Research. 2018; 159: 55-62.
Wang X, Lv C, Ji X, Wang B, Qiu L, Yang Z. Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets. Virus Research. 2019; 263: 80-86.
Nguyen KY, Sakuna K, Kinobe R, Owens L. Ivermectin blocks the nuclear location signal of parvoviruses in crayfish, Cherax quadricarinatus. Aquaculture. 2014;420-421:288-294.
Raza S, Shahin F, Zhai W, et al. Ivermectin Inhibits Bovine Herpesvirus 1 DNA Polymerase Nuclear Import and Interferes with Viral Replication. Microorganisms. 2020;8(3).
Baraka OZ, Mahmoud BM, Marschke CK, Geary TG, Homeida MM, Williams JF. Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus. Eur J Clin Pharmacol. 1996;50(5):407-410.
Crump A. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo). 2017;70(5):495-505.
Muñoz J, Ballester MR, Antonijoan RM, et al. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLoS neglected tropical diseases. 2018;12(1): e0006020-e0006020.
Ivermectin. In: Aronson JK, ed. Meyler's Side Effects of Drugs (Sixteenth Edition). Oxford: Elsevier; 2016:379-390.
Adedokun KA, Olarinmoye AO, Mustapha JO, Kamorudeen RT. A close look at the biology of SARS-CoV-2, and the potential influence of weather conditions and seasons on COVID-19 case spread. Infectious Diseases of Poverty. 2020;9(1):77.
Sharun K, Dhama K, Patel SK, et al. Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19. Annals of Clinical Microbiology and Antimicrobials. 2020;19(1):23.
World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions. 2020; https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions.
This work is licensed under a Creative Commons Attribution 4.0 International License.